1-5 of 5
Hervé Watier
Close
Sort by
Journal Articles

Obinutuzumab: what is there to learn from clinical trials?

Guillaume Cartron, Hervé Watier
Journal: Blood
Blood (2017) 130 (5): 581–589.
https://doi.org/10.1182/blood-2017-03-771832
Published: 2017
Journal Articles

Bacteria and HIT: a close connection?

Yves Gruel, Hervé Watier
Journal: Blood
Blood (2011) 117 (4): 1105–1106.
https://doi.org/10.1182/blood-2010-11-317941
Published: 2011
Journal Articles

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

David Daydé, David Ternant, Marc Ohresser, Stéphanie Lerondel, Sabrina Pesnel, Hervé Watier, Alain Le Pape, Pierre Bardos, Gilles Paintaud, Guillaume Cartron
Journal: Blood
Blood (2009) 113 (16): 3765–3772.
https://doi.org/10.1182/blood-2008-08-175125
Published: 2009
Journal Articles

Efficacy and Safety of Alemtuzumab in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia after Autologous Stem Cell Transplantation.

Caroline Dartigeas, MD, Michel Degenne, PharmD, Delphine Senecal, MD, Philippe Roingeard, PhD, Chantal Cendrie, MD, Martine Delain, MD, Lotfi Benboubker, MD PhD, Claude Linassier, MD PhD, Herve Watier, MD PhD, Christian Binet, MD, Philippe Colombat, MD, Guillaume Cartron, MD PhD
Journal: Blood
Blood (2004) 104 (11): 2509.
https://doi.org/10.1182/blood.V104.11.2509.2509
Published: 2004
Journal Articles

Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.

Olivier Herault, MD, PhD, Florence Dommange, MD, Claire Espanel, MD, Jorge Domenech, MD, PhD, Lotfi Benboubker, MD, PhD, Marc Ohresser, PhD, Philippe Colombat, MD, Christian Binet, MD, Herve Watier, MD, PhD, Guillaume Cartron, MD, PhD
Journal: Blood
Blood (2004) 104 (11): 66.
https://doi.org/10.1182/blood.V104.11.66.66
Published: 2004